Prakt. lékáren. 2015; 11(1): 6-7

Principles of pharmacological pregnancy termination and uterine evacuation

Pavel Trávník
REPROMEDA s. r. o., Brno

Pharmacological pregnancy termination and uterus evacuation is more careful than the surgical methods. Mechanism ot the mifepristone

and misoprostol action is described, as well as the riscs of the surgical and pharmacologic methods, the proces of the drugs application

and current state of application in the Czech Republic.

Keywords: mifepristone, misoprostol, pregnancy termination, uterine evacuation, Asherman syndrome

Published: February 26, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Trávník P. Principles of pharmacological pregnancy termination and uterine evacuation. Praktické lékárenství. 2015;11(1):6-7.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Kulier R, Kapp N, Gülmezoglu AM, Hofmeyr GJ, Cheng L, Campana A. Medical methods for first trimester abortion. Cochrane Database Syst Rev. 2011; (11): CD002855. doi: 10.1002/14651858.CD002855.pub4. Go to original source...
    2. Spencer TE, Bazer FW. Biology of progesterone action during pregnancy recognition and maintenance of pregnancy. Front Biosci. 2002; 7: d1879-1898. Go to original source... Go to PubMed...
    3. Mahajan DK, London SN. Mifepristone (RU486): a review. Fertil Steril. 1997; 68(6): 967-976. Go to original source... Go to PubMed...
    4. Papp C, Schatz F, Krikun G, Hausknecht V, Lockwood CJ. Biological mechanisms underlying the clinical effects of mifepristone (RU 486) on the endometrium. Early Pregnancy. 2000; 4(4): 230-239. Go to PubMed...
    5. Schorge, John O, et al (2008). Williams Gynecology. New York: McGraw-Hill Medical. ISBN 9780071472579.
    6. Adoni A, Palti Z, Milwidsky A, Dolberg M. (1982). The incidence of intrauterine adhesions following spontaneous abortion. Int J Fertil. 27(2): 117-118. PMID 6126446. Go to PubMed...
    7. Tam WH, Lau WC, Cheung LP, Yuen PM, Chung TK. (2002). Intrauterine adhesions after conservative and surgical management of spontaneous abortion. J Am Assoc Gynecol Laparosc. 9(2): 182-185. doi: 10.1016/S1074-3804(05)60129-6. PMID 11960045. Go to original source... Go to PubMed...
    8. Edukační materiál o bezpečném užívání a minimalizaci rizik při použití léčivých přípravků Mifegyne(R) a Mispregnol(R) ve znění schváleném Státním ústavem pro kontrolu léčiv ze dne 11. 11. 2013 a 16. 12. 2013.
    9. Příbalová informace Mifegyne sp.zn. sukls129814/2012.
    10. Příbalová informace Mispregnol Sp.zn. suklsl45625/2013.
    11. Příbalová informace Medabon Sp.zn. sukls162455/2009.
    12. Lown KS, Bailey DG, Fontana RJ, Janardan SK, Adair CH, Fortlage LA, Brown MB, Guo W, Watkins PB. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest. 1997; 99(10): 2545-2553. Go to original source... Go to PubMed...
    13. Vyjádření Ministerstva zdravotnictví k rozhodnutí Státního ústavu pro kontrolu léčiv o registraci přípravků s obsahem léčivé látky mifepriston a misoprostol ze dne 26.06.2013.
    14. Zhang J, Gilles JM, Barnhart K, Creinin MD, Westhoff C, Frederick MM (2005). National Institute of Child Health Human Development (NICHD) Management of Early Pregnancy Failure Trial. A comparison of medical management with misoprostol and surgical management for early pregnancy failure. N Engl J Med. 353(8): 761-769. doi: 10.1056/NEJMoa044064. PMID 16120856. Go to original source... Go to PubMed...
    15. Weeks A, Alia G, Blum J, Winikoff B, Ekwaru P, Durocher J, Mirembe F. (2005). A randomized trial of misoprostol compared with manual vacuum aspiration for incomplete abortion. Obstet Gynecol. 106(3): 540-547. Go to original source... Go to PubMed...

    Return to the content


    Pharmacy for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.